BRUKER CORPORATION (BRKR) Spending and interest coverage
- R&D / revenue · 12 months: Value 11.24%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 11.24% | Research and development expense / revenue. Period ending 2026-06-30. $393.50M ÷ $3.50B × 100 ≈ 11.24% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 393.50M USD | Research and Development Expense |
| Revenue | 3.50B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -30.60M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $393.50M | $3.50B | (m) | $-30.60M | (m) | 11.24% | (m) | (m) | (m) |
| 2026-03-31 | $399.40M | $3.46B | (m) | $46.60M | (m) | 11.55% | (m) | (m) | (m) |
| 2025-12-31 | $395.20M | $3.44B | $20.20M | $68.20M | (m) | 11.50% | 0.59% | (m) | (m) |
| 2025-09-30 | $400.00M | $3.44B | (m) | $64.00M | (m) | 11.63% | (m) | (m) | (m) |
| 2025-06-30 | $399.80M | $3.44B | (m) | $183.90M | (m) | 11.61% | (m) | (m) | (m) |
| 2025-03-31 | $391.80M | $3.45B | (m) | $220.10M | (m) | 11.37% | (m) | (m) | (m) |
| 2024-12-31 | $376.50M | $3.37B | $25.30M | $253.10M | (m) | 11.18% | 0.75% | (m) | (m) |
| 2024-09-30 | $355.60M | $3.24B | $24.70M | $284.50M | (m) | 10.97% | 0.76% | (m) | (m) |
| 2024-06-30 | $328.80M | $3.12B | $24.10M | $340.90M | $29.00M | 10.54% | 0.77% | 11.76× | Reported |
| 2024-03-31 | $307.60M | $3.00B | $22.80M | $379.00M | $17.20M | 10.25% | 0.76% | 22.03× | Reported |
| 2023-12-31 | $294.80M | $2.96B | $24.00M | $436.90M | $16.40M | 9.94% | 0.81% | 26.64× | Reported |
| 2023-09-30 | $274.80M | $2.82B | $22.50M | $464.40M | $16.30M | 9.75% | 0.80% | 28.49× | Reported |
| 2023-06-30 | $259.70M | $2.71B | $22.10M | $471.20M | $16.10M | 9.57% | 0.81% | 29.27× | Reported |
| 2023-03-31 | $248.30M | $2.62B | $26.20M | $458.90M | $16.20M | 9.47% | 1.00% | 28.33× | Reported |
| 2022-12-31 | $235.90M | $2.53B | $27.70M | $432.70M | $16.10M | 9.32% | 1.09% | 26.88× | Reported |
| 2022-09-30 | $230.50M | $2.51B | $28.30M | $427.10M | (m) | 9.20% | 1.13% | (m) | (m) |
| 2022-06-30 | $226.40M | $2.48B | $27.20M | $409.00M | (m) | 9.14% | 1.10% | (m) | (m) |
| 2022-03-31 | $222.60M | $2.46B | $21.40M | $420.70M | (m) | 9.06% | 0.87% | (m) | (m) |
| 2021-12-31 | $220.80M | $2.42B | $17.20M | $413.30M | $14.30M | 9.13% | 0.71% | 28.90× | Reported |
| 2021-09-30 | $219.80M | $2.36B | $17.00M | $400.70M | (m) | 9.31% | 0.72% | (m) | (m) |
| 2021-06-30 | $216.00M | $2.26B | $17.30M | $368.70M | (m) | 9.54% | 0.76% | (m) | (m) |
| 2021-03-31 | $204.30M | $2.12B | $16.50M | $321.00M | (m) | 9.64% | 0.78% | (m) | (m) |
| 2020-12-31 | $198.00M | $1.99B | $16.00M | $248.30M | $14.40M | 9.96% | 0.81% | 17.24× | Reported |
| 2020-09-30 | $187.60M | $1.96B | $10.40M | $253.20M | (m) | 9.57% | 0.53% | (m) | (m) |
| 2020-06-30 | $185.40M | $1.97B | $9.90M | $259.80M | (m) | 9.41% | 0.50% | (m) | (m) |
| 2020-03-31 | $189.80M | $2.04B | $9.80M | $275.40M | (m) | 9.33% | 0.48% | (m) | (m) |
| 2019-12-31 | $187.70M | $2.07B | $9.60M | $300.90M | $16.00M | 9.06% | 0.46% | 18.81× | Reported |
| 2019-09-30 | $185.80M | $2.03B | $13.20M | $289.60M | (m) | 9.17% | 0.65% | (m) | (m) |
| 2019-06-30 | $181.50M | $1.97B | $12.50M | $270.90M | (m) | 9.20% | 0.63% | (m) | (m) |
| 2019-03-31 | $176.60M | $1.93B | $11.90M | $266.20M | (m) | 9.17% | 0.62% | (m) | (m) |
| 2018-12-31 | $173.40M | $1.90B | $11.30M | $262.40M | $12.60M | 9.15% | 0.60% | 20.83× | Reported |
| 2018-09-30 | $172.80M | $1.87B | $10.80M | $246.50M | (m) | 9.23% | 0.58% | (m) | (m) |
| 2018-06-30 | $171.60M | $1.84B | $10.60M | $228.70M | (m) | 9.32% | 0.58% | (m) | (m) |
| 2018-03-31 | $168.30M | $1.81B | $10.90M | $215.20M | (m) | 9.28% | 0.60% | (m) | (m) |
| 2017-12-31 | $162.70M | $1.77B | $11.00M | $214.70M | $15.40M | 9.21% | 0.62% | 13.94× | Reported |
| 2017-09-30 | $157.40M | $1.71B | $11.00M | $197.90M | (m) | 9.23% | 0.64% | (m) | (m) |
| 2017-06-30 | $154.40M | $1.66B | $10.40M | $193.90M | (m) | 9.28% | 0.63% | (m) | (m) |
| 2017-03-31 | $150.50M | $1.62B | $9.80M | $180.80M | (m) | 9.29% | 0.60% | (m) | (m) |
| 2016-12-31 | $149.00M | $1.61B | $9.40M | $177.20M | $13.20M | 9.25% | 0.58% | 13.42× | Reported |
| 2016-09-30 | $147.50M | $1.62B | $9.00M | $171.00M | (m) | 9.11% | 0.56% | (m) | (m) |
| 2016-06-30 | $143.90M | $1.62B | $8.70M | $153.30M | (m) | 8.88% | 0.54% | (m) | (m) |
| 2016-03-31 | $144.60M | $1.65B | $8.00M | $164.50M | (m) | 8.79% | 0.49% | (m) | (m) |
| 2015-12-31 | $145.70M | $1.62B | $8.00M | $145.70M | $13.00M | 8.97% | 0.49% | 11.21× | Reported |
| 2015-09-30 | $150.60M | $1.65B | $8.10M | $119.50M | (m) | 9.11% | 0.49% | (m) | (m) |
| 2015-06-30 | $158.40M | $1.68B | $8.00M | $96.20M | (m) | 9.44% | 0.48% | (m) | (m) |
| 2015-03-31 | $165.40M | $1.74B | $9.60M | $100.00M | (m) | 9.51% | 0.55% | (m) | (m) |
| 2014-12-31 | $174.20M | $1.81B | $9.40M | $105.40M | $13.30M | 9.63% | 0.52% | 7.92× | Reported |
| 2014-09-30 | $181.70M | $1.85B | $8.90M | $121.90M | $13.30M | 9.81% | 0.48% | 9.17× | Reported |
| 2014-06-30 | $185.10M | $1.87B | $8.40M | $148.50M | $13.30M | 9.89% | 0.45% | 11.17× | Reported |
| 2014-03-31 | $187.10M | $1.87B | $6.80M | $156.60M | $13.30M | 10.01% | 0.36% | 11.77× | Reported |
| 2013-12-31 | $190.50M | $1.84B | $6.60M | $148.20M | $13.40M | 10.36% | 0.36% | 11.06× | Reported |
| 2013-09-30 | $191.70M | $1.80B | $6.70M | $126.40M | $13.50M | 10.62% | 0.37% | 9.36× | Reported |
| 2013-06-30 | $191.10M | $1.81B | $7.20M | $155.20M | $13.70M | 10.54% | 0.40% | 11.33× | Reported |
| 2013-03-31 | $196.50M | $1.78B | $7.70M | $133.80M | $14.10M | 11.04% | 0.43% | 9.49× | Reported |
| 2012-12-31 | $195.30M | $1.79B | $7.80M | $156.00M | $14.30M | 10.90% | 0.44% | 10.91× | Reported |
| 2012-09-30 | $189.70M | $1.75B | $8.00M | $170.50M | $13.20M | 10.84% | 0.46% | 12.92× | Reported |
| 2012-06-30 | $188.30M | $1.72B | $7.90M | $147.70M | $11.30M | 10.95% | 0.46% | 13.07× | Reported |
| 2012-03-31 | $180.70M | $1.70B | $8.00M | $164.30M | $9.30M | 10.63% | 0.47% | 17.67× | Reported |
| 2011-12-31 | $177.20M | $1.65B | $7.90M | $155.60M | $7.30M | 10.73% | 0.48% | 21.32× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $141.40M | $1.30B | $6.90M | $155.70M | $5.60M | 10.84% | 0.53% | 27.80× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $126.40M | $1.11B | $6.30M | $136.70M | $7.50M | 11.34% | 0.57% | 18.23× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |